• Afatinib in Gastric Cancer Assembloid Research

  2026-08-30

  Afatinib, also known as BIBW 2992, enables controlled studies of irreversible ErbB blockade in patient-derived gastric cancer models. Integrated with matched tumor organoids and stromal subpopulations, it helps reveal when tumor–microenvironment interactions alter pathway dependence, drug sensitivity, and resistance.

• HyperScribe SP6 High Yield RNA Synthesis Kit Workflows

  2026-08-29

  Build reliable RNA production workflows for probes, functional transcripts, and immune-pathway assays with the HyperScribe SP6 High Yield RNA Synthesis Kit. Its high-output SP6 transcription format supports both routine RNA generation and specialized capped, biotinylated, dye-labeled, or radiolabeled applications.

• Localized BDNF Release in Early NMJ Assembly

  2026-08-28

  The reference study shows that muscle-generated BDNF is trafficked to podosome-like structures and released locally to initiate acetylcholine receptor clustering during early neuromuscular junction development. By combining live imaging, molecular perturbation, and muscle-specific knockout mice, it links BDNF localization, activity-dependent secretion, and proteolytic processing to postsynaptic assembly.

• Cheminformatics for Optimized Small-Molecule Libraries

  2026-08-28

  Moret et al. present a data-driven framework for comparing and designing small-molecule collections using target coverage, binding selectivity, cellular phenotypes, chemical structure, clinical status, and user preferences. The resulting LSP-OptimalKinase and LSP-MoA libraries show how computational optimization can produce compact collections with broader coverage and less redundant off-target activity.

• U-73122 for PLC Signaling and Invasion Assays

  2026-08-27

  U-73122 is a practical phospholipase C inhibitor for connecting PLC activity with calcium flux, neutrophil chemotaxis, inflammation, and cancer-cell invasion. This guide translates its mechanism into assay-ready workflows, controls, and troubleshooting decisions.

• N6-Methyl-dATP for Mechanism-First DNA Assays

  2026-08-27

  N6-Methyl-dATP enables a mechanism-first approach to polymerase recognition, DNA replication fidelity study, and methylation modification research. This article connects the nucleotide probe to the LMO2/LDB1 AML literature while defining practical assay boundaries and translational limitations.

• Dasatinib (BMS-354825) Experimental Workflows

  2026-08-26

  Dasatinib (BMS-354825) gives researchers a practical way to interrogate Src and Bcr-Abl signaling, focal-adhesion biology, and metastatic behavior across complementary cancer models. This guide converts published activity data into reproducible workflows while separating validated findings from exploratory EMT and tumor-microenvironment applications.

• Anlotinib Hydrochloride: Mechanism and Assays

  2026-08-26

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that suppresses VEGFR2, PDGFRβ, and FGFR1 signaling in angiogenesis models. Its nanomolar activity, low observed assay cytotoxicity, and defined pharmacokinetic profile support controlled cancer research workflows rather than un supervised clinical use.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib

  2026-08-25

  The reference study identifies TRIB3 as a contributor to clear cell renal cell carcinoma resistance to Sunitinib and shows that TRIB3 depletion enhances ferroptotic cell death through the SLC7A11/GPX4 axis. Its findings provide a mechanistic basis for testing TRIB3-directed strategies alongside RTK inhibition, while emphasizing that the evidence remains primarily preclinical.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-25

  Song et al. show that murine norovirus exploits the membrane-rupture factor NINJ1 to release the viral immune-modulatory protein NS1 through an unconventional, caspase-3-dependent pathway. The study combines genetic screening, cell biology, protein-interaction analysis, mutagenesis, and mouse infection models to connect selective viral protein secretion with enteric infection.

• Sunitinib: RTK Inhibition in Cancer Research

  2026-08-24

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor used to study VEGFR-, PDGFR-, KIT-, and RET-dependent tumor biology. Its research value includes angiogenesis suppression, apoptosis induction in renal cell carcinoma models, and cell cycle arrest at G0/G1 phase, while solubility and resistance require controlled experimental design.

• PEI-Laminarin Nanoparticles Boost OVA Vaccination

  2026-08-24

  The reference study developed polyethyleneimine-modified laminarin nanoparticles that combine cationic antigen loading with polysaccharide-based immune stimulation. In an ovalbumin model, the formulation improved dendritic-cell uptake, maturation, lysosomal escape, antigen cross-presentation, and both humoral and cellular immune responses relative to aluminum adjuvant.

• Imatinib Hydrochloride: From Binding to Assay Design

  2026-08-23

  Imatinib hydrochloride is a benchmark multi-target kinase inhibitor for chronic myelogenous leukemia and gastrointestinal stromal tumor research. This guide connects its ATP-site pharmacology with emerging kinase–phosphatase assay concepts while separating established evidence from testable hypotheses.

• NADH Workflows for Redox and Mitochondrial Research

  2026-08-22

  Build reproducible NADH experiments around fresh reagent handling, paired NADH/NAD⁺ measurements, and orthogonal validation. This guide connects practical cell and mitochondrial workflows with biosensor-guided screening, diabetic nephropathy research, Leigh syndrome models, and photocatalytic cancer therapy while clearly separating established findings from assay recommendations.

• (S)-(+)-Dimethindene maleate Protocol Guide

  2026-08-22

  This practical guide helps researchers use (S)-(+)-Dimethindene maleate as a dossier-defined M2 muscarinic receptor antagonist while accounting for its additional histamine H1 receptor antagonism. It is intended for controlled pharmacological experiments, not diagnostic, therapeutic, or medical use, and prepared solutions should be used promptly rather than stored long term.

8370 records 4/558 page Previous Next 12345 下5页 Last page